OPKO Provides Update on the Development of OPK-88004, a Selective Androgen Receptor Modulator Jan 31, 2019
OPKO Health and OPKO's CEO and Chairman, Dr. Phillip Frost, Announce Proposed Resolution of SEC Action Dec 27, 2018